BioCentury
ARTICLE | Management Tracks

Ex-Sanofi CMO Nathwani to lead Dewpoint; plus Inozyme, ReCode and Frazier

October 14, 2020 12:39 AM UTC

Dewpoint Therapeutics hired Ameet Nathwani as CEO and a member of the board of directors. Nathwani joins the biomolecular condensates company from Sanofi (Euronext:SAN; NASDAQ:SNY), where he was CMO, chief digital officer and a member of the executive committee. Over a biopharma career than has spanned more than two decades, Nathwani has led the development of more than 20 drugs and, at Sanofi, oversaw the development of a real-world evidence data platform. He succeeds Polaris Partners Managing Partner and Dewpoint Chairman Amir Nashat as CEO. Late last month, Dewpoint raised $77 million in a series B round led by Arch Venture.

Inozyme Pharma Inc. (NASDAQ:INZY) hired Yves Sabbagh as SVP and CSO to succeed David Thompson, who is retiring. Sabbagh was previously the head of rare renal and musculoskeletal diseases research at Sanofi. Inozyme is developing therapeutics to treat rare diseases of abnormal mineralization affecting the vasculature, soft tissue and skeleton. ...